Leerink analyst Joseph Schwartz raised his price target for uniQure (QURE) to $76 from $61 as positive dose-confirmation data reaffirms his optimism for AMT-061 in hemophilia B. The analyst believes that uniQure's first attempt at using the Padua variant has shown early success and gives him incremental confidence heading into Phase 3 HOPE-B study, with patient dosing anticipated to commence in Q1 of 2019. Additionally, Schwartz argues that first data using the Padua variant looks "competitive" against Spark Therapeutics' (ONCE) SPK-9001. He reiterates an Outperform rating on uniQure's shares.